632626-08-5

Upstream product

• 100-39-0 benzyl bromide 
• 210039-65-9 2-hydroxy-5-(trifluoromethyl)benzaldehyde 
• 134142-88-4 2-[(4-trifluoromethyl)phenoxy]tetrahydro-2H-pyrane 
• 402-45-9 4-hydroxybenzotrifluoride 
• 888972-21-2 2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)benzaldehyde 

Downstream Products

• 1253113-55-1 1-(benzyloxy)-2-(bromomethyl)-4-(trifluoromethyl)benzene 
• 632627-25-9 6-{2-[5-trifluoromethyl-2-(benzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-2-bromopyridine 
• 632627-26-0 6-{2-[5-trifluoromethyl-2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-picolinic acid 
• 632622-28-7 3-{2-[5-trifluoromethyl-2-(2-chloro-4-fluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid 
• 632623-87-1 6-{2-[5-trifluoromethyl-2-(2,3-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-picolinic acid 
• 632622-29-8 3-{2-[5-trifluoromethyl-2-(2,4-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid 
• 632623-88-2 6-{2-[5-trifluoromethyl-2-(2,6-difluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-picolinic acid 
• 632622-27-6 3-{2-[5-trifluoromethyl-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid 
• 632622-26-5 3-{2-[5-trifluoromethyl-2-(4-chlorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid 
• 632623-86-0 6-{2-[5-trifluoromethyl-2-(4-fluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-picolinic acid 
• 632626-11-0 3-{2-[5-trifluoromethyl-2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid ethyl ester 
• 632626-10-9 3-{2-[5-trifluoromethyl-2-(benzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-benzoic acid ethyl ester 
• 632626-09-6 1-[5-trifluoromethyl-2-(benzyloxy)-phenyl]-pentane-1,4-dione 

Relevant academic research and scientific papers

Versatile Nickel(II) Scaffolds as Coordination-Induced Spin-State Switches for 19F Magnetic Resonance-Based Detection

19F magnetic resonance (MR) based detection coupled with well-designed inorganic systems shows promise in biological investigations. Two proof-of-concept inorganic probes that exploit a novel mechanism for 19F MR sensing based on con

Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists

The preliminary SAR of a series of novel 1,5-biaryl pyrrole EP1 receptor antagonists derived from compound 1 is described. Replacement of the benzyl group of 1 with isosteric groups was investigated. The most effective replacement was found to be the isobutyl group. The cyclopentylmethyl and cyclohexylmethyl groups were also effective benzyl replacements. The cyclohexylmethyl derivative 19 demonstrated the lowest metabolic clearance within this series. In addition, several high affinity substituted benzyl analogues were also identified. Compound 39 was found to have good bioavailability in rats and demonstrated efficacy in the established FCA preclinical model of inflammatory pain with a calculated ED50 of 9.2 mg/kg.

PYRROLE COMPOUNDS

Compounds of formula (I) or a derivative thereof: wherein A, B, Z, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such

PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.